Compare Immunovant Inc. Common Stock (IMVT) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Viasat — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Viasat trades at $69.48 (market cap $9.76B). The key difference: Viasat is the larger of the two by market cap, and Viasat is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Viasat for 10 Days on average.
| IMVT | VSAT | |
|---|---|---|
Market Cap | $6.62B | $9.76B |
Volume | 1,131,364 | 1,739,997 |
Sector | Health | Technology |
52-Week High | $44.96 | $89.81 |
52-Week Low | $17.03 | $30.35 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $5.72B | $14.95B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
